All In Biotech

Drug Trial Radar · NCT07951463

A Study of Glumetinib in Combination With Osimertinib as 1st Line Treatment in Patients With Non-Small Cell Lung Cancer

A Multicenter, Randomized, Controlled Phase Ⅲ Clinical Study on the Efficacy and Safety of Glumetinib in Combination With Osimertinib as First-Line Treatment in Patients With Non-Small Cell Lung Cancer With Classic EGFR Mutations and MET Overexpression or Amplification

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 375 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

375

Planned (sponsor's estimate)

Start

Dec 31, 2026

Primary completion

Apr 30, 2029

Study completion Aug 31, 2030

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Nov 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of Glumetinib plus Osimertinib in patients with non-small cell lung cancer with classic EGFR mutations and MET overexpression or amplification.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • Glumetinib TabletsDrug

    Glumetinib 300 mg QD orally under fasting conditions

  • PlaceboDrug

    Placebo 300 mg QD orally under fasting conditions

  • Osimertinib Mesylate TabletsDrug

    Administered orally at a dose of 80 mg QD orally

  • Pemetrexed/CarboplatinDrug

    Pemetrexed (500 mg/m2) plus carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

  • Pemetrexed/CisplatinDrug

    Pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by Osimertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. FS as assessed by IRCTime frame: Up to approximately 42 months after the first patient is enrolled

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.